Senores Pharmaceuticals Limited announced its un-audited financial results for the third quarter and nine months ended December 31, 2025. The company reported a consolidated Profit After Tax (PAT) of ₹34 crore for Q3FY26, marking a significant increase of 105% compared to the same period last year. Total income for the quarter grew by 64% year-on-year to ₹175 crore, with EBITDA also rising by 86% to ₹54 crore.

For the nine-month period ended December 31, 2025 (9M FY26), consolidated PAT surged by 110% to ₹85 crore on a 65% increase in total income to ₹474 crore. EBITDA for the nine months grew by 87% to ₹138 crore.

The company highlighted strong performance in its Regulated Markets, with Q3 FY26 revenue growing by 60.5% year-on-year to ₹112.7 crore and EBITDA margin at 40%. For 9M FY26, revenue stood at ₹309.6 crore, a 71.5% year-on-year growth, also with an EBITDA margin of 40%.

In Emerging Markets, Q3 and 9M FY26 revenues were ₹38.4 crore and ₹61 crore, respectively, with EBITDA margins at 13% and 9%. The company achieved its highest-ever quarterly revenue and EBITDA in Emerging Markets in Q3 FY26, with the business now being cash flow positive.

Senores Pharmaceuticals also provided an update on the acquisition of Apnar Pharmaceuticals, completing Phase 1 with a 75% stake acquisition. Phase 2, involving the remaining 25%, is expected to be completed by Q2FY27. Three out of five approved ANDAs from Apnar are slated for launch in Q4FY26.

Managing Director Swapnil Shah commented that the company is on track to deliver its full-year guidance, driven by four key pillars: expansion of the ANDA portfolio in Regulated Markets, scale-up of the CDMO/CMO segment, improved profitability in Emerging Markets, and scaling up the Branded Generics business in India.